REFERENCES
- Akduman B, Crawford E D. Terazosin, doxazosin, and prazosin: Current clinical experience. Urology 2001; 58(6 Suppl. 1)49–54
- Dunn C J, Matheson A, Faulds D M. Tamsulosin: A review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 2002; 19: 135–161
- Kaplan S A, De Rose A F, Kirby R S, O'leary M P, McVary K T. Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health. BJU Int 2006; 97: 559–566
- Yono M, Yamamoto Y, Yoshida M, Ueda S, Latifpour J. Effects of doxazosin on blood flow and mRNA expression of nitric oxide synthase in the spontaneously hypertensive rat genitourinary tract. Life Sci 2007; 81: 218–222
- Andersson K E, Chapple C R, Hofner K. Future drugs for the treatment of benign prostatic hyperplasia. World J Urol 2002; 19: 436–442
- Schwinn D A. The role of α1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 2001; 88(Suppl. 2)27–34
- Giardinà D, Gulini U, Massi M, Piloni M G, Pompei P, Rafaiani G, Melchiorre C. Structure-activity relationships in prazosin-related compounds. 2. Role of the piperazine ring on α-blocking activity. J Med Chem 1993; 36: 690–698
- Pescalli N, Sala V, Sponer G, Ceserani R. Effects of naftopidil on some urodynamic parameters and arterial blood pressure in comparison with prazosin in conscious rats. Pharmacol Res 1996; 34: 121–124
- Yono M, Takahashi W, Pouresmail M, Johnson D R, Foster H E, Jr, Weiss R M, Latifpour J. Quantification of endothelins, their receptors, and endothelin-converting enzyme mRNAs in rat genitourinary tract using real-time RT-PCR. J Pharmacol Toxicol Methods 2002; 48: 87–95
- Nishi K, Wada Y, Saito M, Foster H E, Jr, Weiss R M, Latifpour J. Properties of alpha-1-adrenergic receptors in the rat prostate: Effect of experimental diabetes. Urol Int 1998; 61: 147–153
- Persson K, Pandita R K, Spitsbergen J M, Steers W D, Tuttle J B, Andersson K E. Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol 1998; 275: R1366–R1373
- Steers W D, Clemow D B, Persson K, Sherer T B, Andersson K E, Tuttle J B. The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males. Exp Physiol 1999; 84: 137–147
- Golomb E, Rosenzweig N, Eilam R, Abramovici A. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J Androl 2000; 21: 58–64
- Hale T M, Okabe H, Bushfield T L, Heaton J P, Adams M A. Recovery of erectile function after brief aggressive antihypertensive therapy. J Urol 2002; 168: 348–354
- Lepor H. The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. Rev Urol 2006; 8(Suppl. 4)S3–S9
- Lepor H, Jones K, Williford W. The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study. J Urol 2000; 163: 1134–1137
- Takei R, Ikegaki I, Shibata K, Tsujimoto G, Asano T. Naftopidil, a novel α1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human α1-adrenoceptors. Jpn J Pharmacol 1999; 79: 447–454
- Hampel C, Dolber P C, Smith M P, Savic S L, Th roff J W, Thor K B, Schwinn D A. Modulation of bladder α1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 2002; 167: 1513–1521
- Sugaya K, Nishijima S, Miyazato M, Ashitomi K, Hatano T, Ogawa Y. Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats. Neurosci Lett 2002; 328: 74–76
- Gotoh M, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Origasa H. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: A randomized controlled trial. BJU Int 2005; 96: 581–586
- Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T. Comparison of two α1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: A randomized crossover study. BJU Int 2006; 97: 747–751
- Tarcan T, Azadzoi K M, Siroky M B, Goldstein I, Krane R J. Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Br J Urol 1998; 82(Suppl. 1)26–33
- McVary K T. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005; 47: 838–845